Drug Search Results
Using advanced filters...
Advanced Search [+]

Epoetin zeta

Alternative Names: epoetin zeta
Latest Update: 2023-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EPO Agonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Croatia | Cyprus | Estonia | France | Germany | Hungary | Malaysia | Norway | Portugal | Spain | Turkey | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: STADA R&D
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Preleukemia|Myelodysplastic Syndrome

Phase 3: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RETA

P4

Completed

Myelodysplastic Syndrome|Preleukemia

2017-05-01

Epoetin STADA s.c. vs. Erypo® s.c. as maintenance treatment of renal anemia

P3

Completed

Kidney Diseases

2010-04-19

Recent News Events